Michael Pohlod, MD
Ophthalmology · Orlando, FLNPI 1316904774
Payments from drug & device makers
Across 126 payments — averaging $37.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alcon$897
- Sun Pharmaceutical Industries Inc.$399
- Aerie Pharmaceuticals, Inc.$369
- Bausch & Lomb, A Division Of Bausch Health US, LLC$317
- Rxsight Inc$313
- plus $1K from 9 others
What the payments were for
- Food & beverage$4,701100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $1,170 |
| Alcon | 16 | $897 |
| Sun Pharmaceutical Industries Inc. | 10 | $399 |
| Aerie Pharmaceuticals, Inc. | 8 | $369 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $317 |
| Rxsight Inc | 3 | $313 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $300 |
| Amgen | 2 | $239 |
| Novartis | 7 | $213 |
| Bausch & Lomb Americas Inc. | 6 | $212 |
| Harrow Eye, LLC | 6 | $132 |
| Oyster Point Pharma, Inc. | 4 | $88 |
| Biotissue Holdings Inc. | 1 | $22 |
| Rayner Intraocular Lenses Limited | 1 | $15 |
| Kala Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$454
- Rocklatan$352
- ARGOS$250
- CEQUA$241
- Rhopressa$241
- TEPEZZA$239
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$155
- RXSIGHT CONTACT LENS$139
- RXSIGHT INJECTOR CARTRIDGE$139
- RXSIGHT INJECTOR HANDPIECE$139
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$139
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$139
- Clareon$138
- LenSx$130
- DURYSTA$126
- Tecnis Multifocal Family of 1-piece IOLS$125
- Tecnis iTec Preloaded Delivery System$125
- Tecnis Toric 1-piece IOL$125
- Tecnis Simplicity$113
- TRAVATAN Z$105
How this compares
$4,701 in reported general payments places this provider in the 70th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 366 | $322,538 |
| LumiganBimatoprost | 559 | $318,033 |
| CombiganBrimonidine Tartrate/Timolol | 225 | $101,409 |
| RocklatanNetarsudil Mesylat/Latanoprost | 129 | $100,392 |
| Prednisolone Acetate | 1,288 | $65,251 |
| Latanoprost | 3,416 | $45,880 |
| Restasis MultidoseCyclosporine | 36 | $41,707 |
| Cyclosporine | 55 | $25,279 |
| XiidraLifitegrast | 27 | $25,263 |
| Travoprost | 136 | $24,832 |
| RhopressaNetarsudil Mesylate | 36 | $22,686 |
| MoxifloxacinMoxifloxacin Hcl | 857 | $20,684 |
| Ketorolac Tromethamine | 1,050 | $20,410 |
| CequaCyclosporine | 25 | $19,880 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,258 | $19,554 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Restasis Multidose, Alphagan P | $1,170 | $792,1211,208 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $369 | $123,078165 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $212 | $43,87363 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $399 | $19,88025 claims |
| AlconSimbrinza | $897 | $9,50334 claims |
| NovartisTravatan Z | $213 | $6,08916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Orlando
- Matthew CunninghamOrlando$2.9M
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.